Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 6.6% – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) fell 6.6% on Wednesday. The stock traded as low as $14.85 and last traded at $15.03. Approximately 4,078 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 6,815 shares. The stock had previously closed at $16.09.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. BTIG Research reiterated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective for the company. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Stock Down 7.2%

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The stock has a 50-day moving average of $16.90 and a 200-day moving average of $19.46.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million for the quarter. Equities analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.